Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
8 November 2012 | By Novartis
Update on leading R&D pipeline...
List view / Grid view
News
Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes
8 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…
Merck announces FDA acceptance of New Drug Application for Suvorexant, an investigational insomnia medicine
8 November 2012 | By Merck
Merck announced that the NDA for suvorexant has been accepted for standard review...
FOSS releases new version of Vision
8 November 2012 | By FOSS NIRSystems Inc.
FOSS NIRSystems, Inc. has introduced Vision 3.60. Vision is a software package specifically designed for use with the FOSS NIRSystems NIR laboratory & process analyzers...
Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration
8 November 2012 | By Merck
The Regenstrief Institute and Merck have signed a five-year agreement...
Auxilium and Pfizer will conclude agreement on XIAPEX® EU collaboration
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
Novartis drug Signifor® recommended by FDA advisory committee for approval to treat patients with Cushing’s disease
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
7 November 2012 | By Novartis
RELAX-AHF study met one of its two primary endpoints...
U.S. Food and Drug Administration approves Pfizer’s XELJANZ® (tofacitinib citrate)
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
Takeda to acquire Envoy Therapeutics, Inc.
6 November 2012 | By
Gains innovative research platform-bacTRAP technology and adds novel CNS programs...
Janssen announces collaboration with Vertex on phase 2 study
5 November 2012 | By
To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C...
AMG 145 significantly reduced LDL cholesterol in patients
5 November 2012 | By
Results from RUTHERFORD study presented at American Heart Association Scientific Sessions 2012...
Pradaxa® – Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations
5 November 2012 | By Boehringer Ingelheim
New findings presented...
FDA and EMA reaffirm important health benefits and safety of Pradaxa® for patients with atrial fibrillation
5 November 2012 | By Boehringer Ingelheim
"We welcome the positive conclusions reached..."
Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC
5 November 2012 | By Novartis
European Commission approval for Votubia®...
